Company News

Perotti & Carson Joining Semex

Semex is pleased to announce two key additions to its global team in March 2019. Charlie Perotti has accepted the role of Director, Corporate Account Programs effective Monday, March 18 and Mark Carson has accepted the position of Genetic Solutions Manager, effective Monday, March 25.
Reporting to Paul Krueger, Vice President, Global Key Account & Solutions Strategies, Charlie will play a key role in furthering Semex's global corporate account strategies and sales growth within key markets including: Mexico; Russia; China; and South East Asia.
Charlie has a lifetime of experience in the global dairy industry, focusing on progressive dairy herd genetic development and management. Most recently he was the Production Director at Fonterra in Beijing, China, managing their 32,000 milking cows. Charlie's vast experience touches all facets of the dairy industry including management, sales, sales management, employee sourcing, training and development. A third-generation dairy farmer, Charlie is also a general partner in his family's century farm.
Mark will lead the support and development of new and existing genetic solutions as part of the Semex Solutions Team, reporting to Jay Shannon, Director, Genetic Programs & Solutions.
Mark has been employed with EastGen over the past 10 years, most recently in the role of Solutions Manager, leading a team of field specialists supporting Semex ai24® and Semex Solutions on key dairies throughout Ontario and Atlantic Canada. Mark has a BSc in Animal Science and an MSc in Epidemiology from the Ontario Veterinary College, University of Guelph.
Semex is pleased to have these two well-known dairy industry persons join our global team, delivering the best client services, support and product globally.

... Read More...

SEMEX'S FASTSTART SIRES DELIVER WORLD'S BEST GENOMICS EVEN FASTER

Semex is excited to announce the launch of FastStart sires, genomic sires delivered at the fastest pace possible!   “Genomics and the new release high genomic young sires are driving the genetics business,” comments Brad Sayles, Semex Chief Operating Officer. “At Semex, we want clients to have access to our highest-ranking sires just as fast as possible. FastStart helps them do that. By signing up for this program, clients everywhere can have the hottest young sires available, and be the first to do it!”   FastStart represents the best, high-ranking Holstein and Jersey sires from diverse pedigrees. Released monthly, FastStart sires will be high ranking GTPI, PTAT, JPI, JUI and excel in health traits.   “Signing up for FastStart is easy,” says Sayles. “Clients will see that we’re offering the most elite genetics to them first at extremely competitive pricing, and with the option for Semex to have access to the resulting genetics there is no financial risk. Once you’re on board you will be the first to get the very best 200 code sires!”   For more information on Semex, FastStart sires or our solutions portfolio please visit www.semex.com      
... Read More...

Semex Part Of New Angus Genome Project Aimed At Reducing BRD

This week, the Honourable Kirsty Duncan, Canada's Minister of Science and Sport, announced $56 million in funding to support 37 research projects. This includes Semex's new joint project with the University of Guelph's Dr. Bonnie Mallard, the Angus Genetics Inc and Canadian Angus Association dedicated to fighting Bovine Respiratory Disease (BRD) in Angus Beef cattle. This project received over $500,000 in funding from Genome Canada's Genomic Application Partnership Program.    "We've already done this for dairy cattle with our partner Semex," says Dr. Mallard. "It will provide three major benefits. The first is to the animal, because healthier animals are better off all the way around. The second is to the producer. They save time and money because they don't have to spend time treating sick animals with antibiotics or other therapeutics as much as they would under normal circumstances. And the third benefit is to the consumer, of course, because you (the consumer) can sit with confidence when you eat that steak, knowing that it came from naturally healthy animals, that were produced in a healthy and sustained environment."   BRD is the most common and costly disease affecting feedlot cattle in North America, with estimates to be as high as $1 billion annually. Unfortunately, pharmaceuticals are temporary solutions, with antimicrobial resistance growing and antibiotics are becoming less effective over time. Additionally, the meat industry is facing mounting pressure to phase out antibiotic use, with supply chains responding to consumer demand.   "Semex is taking our Immunity+® technology to the beef industry," says Dr. Michael Lohuis, Semex Vice President Research & Innovation. "With Dr. Mallard, the Angus Genetics Inc and Canadian Angus Association, we're developing a High Immune Response test for Angus cattle. BRD is a costly disease, and we think we could reduce those costs by up to 50%! Our goal is to develop a more sustainable beef product for ... Read More...

Semex's Millionaire Sire Manifold Passes Away

Semex is saddened to announce that its 12th Millionaire Sire, 0200HO00402 Mainstream Manifold, has passed away.
Manifold was from a strong cow family known for production and was backed by eight generations of VG or EX dams. He combined this strong maternal line at Mainstream Holsteins in Washington, with type strength and desirable health and fertility traits to be one of the most predictable sires in Semex’s lineup for nearly a decade.
A truly unfaltering sire, Manifold debuted as the #20 TPI sire in August 2009. As time  passed, he only gained strength as he added daughters reaching the coveted Millionaire Status in April 2014 when he was also the breed’s #12 TPI and #6 LPI sire.
With over 73,000 daughters in his production proof in December 2018, Manifold continued to be one of the most popular O Man sons of our time, offering solid production, great components and a breed leading 3.9% Sire Calving Ease.
"Manifold was a truly exceptional bull and was a great example of our commitment to providing healthy, long-lasting cows to our clients,” says Brad Sayles, Chief Operating Officer. “And, he was a stand-out among O Man sons. He really did it all, being a Millionaire and selling to all corners of the world. We’re fortunate to have a limited quantity of Manifold semen still available, allowing dairymen to continue using this profitable and popular Millionaire Sire.”

... Read More...

Semex's Elevate Female Immunity Test Wins World Ag Expo Top-10 New Products Competition

The Top-10 New Product Award Competition is conducted annually by the International Agri-Center®, in conjunction with World Ag Expo® (WAE). Nominations are submitted by WAE exhibitors and judged by farmers, ranchers and industry professionals. This year, Semex’s Elevate™ Female Immunity Test is one of the Top-10 winners and will be recognized at the show held February 12-14 in Tulare, California!
Launched on December 4, 2012, Immunity+ was billed as an industry first – an exclusive product that would dramatically change the way dairymen developed their own breeding strategies and managed herd health. With Elevate, its female genomic testing program, Semex offers a genomic test that ranks and selects cows for both their Immunity+ genomic results and their genetic merit!
With Elevate and the Immunity+ genomic test, there’s no more guess work as to which cows will better resist disease. Armed with both genomic information and Immunity+ results, producers are able to make faster genetic progress towards a stronger, more disease resistant herd, reducing losses and drug use. Immunity+ heritability is 30%, similar to that of milk production. Semex is excited to be the only AI company to deliver uncompromised herd health gains that can be made by identifying both female immune response and utilizing Immunity+ sires.
"With Elevate and its Immunity+ genomic test, producers no longer have to guess which cows are their healthiest," says Gordon Miller, Semex Sr. Vice President, Sales & Business Development. "Instead, they're able to tailor their breeding program with both genomic information as well as Immunity+ results categorized as high, average or low health. They make faster genetic progress towards a stronger, more disease resistant herd, reducing losses and drug use. Immunity+ heritability is 30%, similar to that of milk production. We're excited for herd health gains that can be made by both identifying female health and ... Read More...

Building Strength With Immunity+

Immunity+ disease-resistant genetics now represents 37% of Semex dairy sales. What started as a research project more than 20 years ago, before Semex was established, has indeed changed the game.

Semex Geneticist and Business Analyst Dr. Steven Larmer believes there are many reasons for the growth of Immunity+, but the ultimate measure of the genetic program’s success is the confidence dairy producers have in its ability to improve the health of their herd.

Recently, research work with the University of Guelph has put a dollar value on the return producers can expect from their Immunity+ investment. These studies show Immunity+ sired daughters show less disease, saving dairymen $72 per cow, from birth to the end of first lactation.

BENEFITTING FROM HIGH IMMUNITY
Larmer says measuring financial payback is important but when he talks to producers it’s obvious that Immunity+ has an event greater impact. “High immune response means cows get sick less often, they are more productive and more profitable. Ultimately, no farmer wants to deal with sick cows. You can spend your time on the farm doing other things that are much more productive and satisfying.”

Many producers point to fewer cases of mastitis and less lameness when describing Immunity+ benefits, but Larmer believes it’s the total package that gives this technology an edge. “Overall, we try to not focus too much on the individual health event. The big difference with Immunity+ is we’re selecting cows that are going to be resistant to any disease that comes their way,” explains Larmer. “We really focus on how the whole immune system works, and making sure an animal’s entire immune system is robust, and effective.”

When animals have strong immune systems, farmers will see a positive impact on every disease present on a dairy ... Read More...

264 REASONS TO USE IMMUNITY+®

In December, Semex is proud to announce it now has 264 reasons to use Immunity+!
“We’re excited about our Immunity+ lineup,” says Semex’s Paul Krueger, VP, Global Key Account & Solutions Strategy. “We now have 264 sires that have been tested to be Immunity+. This is your fastest, best option to breed a healthier herd. And, with this many choices, we know Semex has the Holstein, Jersey or Ayrshire bull that will meet your genetic criteria.”  
Dr. Steven Larmer, Semex Geneticist & Business Analyst concurs, “Despite all of the improvements made with dairy animal husbandry there continues to be worse health performance. When all else is equal, the thing that's going to differ between two cows on your dairy is, 'how strong is their immune system? How able are they going to be to respond to that challenge?' Because no matter how well-managed a dairy is, every cow is going to encounter both bacterial and viral pathogens almost every day," Larmer says.
Launched on December 4, 2012, Immunity+ was billed as an industry first – an exclusive product that would dramatically change the way dairymen developed their own breeding strategies and managed herd health.
Six years later, dairymen worldwide are seeing the results. A study of Semex sired animals from 35 commercial dairies in 2017 showed improvements in a number of areas on about 30,000 cows and 75,000 heifers tested. The reductions were seen in eight health incidences, with the most significant being a 20% reduction in mortality and 17% reduction in persistent mastitis. The improvements in immune response would have resulted in $72,330 savings for herds milking 1,000 cows during one lactation period.
In December, Semex is proud to offer 264 Immunity+ sires including:
41 Holstein sires over +2600 GTPI 14 Holstein sires over +800 NM$ 46 Jersey Immunity+ sires 11 Ayrshire Immunity+ sires
As Semex’s lineups grow, 200 ... Read More...

Semex Giving Away Two Calves Genomically Tested For Immunity At World Dairy Expo

The best giveaway at World Dairy Expo is healthier than ever! Semex is breaking ground once again by giving away two heifers that are genomically tested to be high immune responders.

“We all know that a healthier herd is a more profitable herd,” says Michael Hurst, Semex Director, US Sales & Business Development. “And this year at our tent, we’re actually giving away two high GTPI heifers that have been genomically tested to be more resistant to disease. They’re healthier than other calves and their genomics proves it. We’re the only company that has this test and the only exhibitor at World Dairy Expo that can literally give you a healthier herd…. All you need to do is come and enter!”   

Launched in early 2018, Semex’s Elevate™ program is a genomic testing program that is unique in many ways, including that it is the only test that offers an Immunity female test. This means producers no longer have to guess which cows are their healthiest. Instead, Elevate helps tailor their breeding program with both genomic information and Immunity results, making faster genetic progress towards a stronger, more disease resistant herd.

“We used Elevate for our own testing,” says Paul Krueger, VP, Global Key Account & Solutions Strategy. “The results are easy to follow, with a designation of low, medium or high for Immune Response. These heifers were high responders, meaning they’re more resistant to common diseases. Stopping by the Semex Tent at World Dairy Expo and entering to win one of these calves could be just the start of a healthier herd for you with Semex!”

Enter to win one of these calves at the Semex Tent during World Dairy Expo, join us for hospitality from 5:00-7:00 pm on Thursday and Friday nights, with a live calf draw at 6:00 pm both nights. Winners need not be ... Read More...

SEMEX INTERNATIONAL SALES & SUPPORT DEPARTMENTS GROW

Semex is pleased to announce the appointment of two individuals to key positions within the organization:


Matthew McCready has accepted the role of Director, International Sales & Business Development, effective September 10, 2018
Peter Van Beek has accepted the role of Key Account Manager, effective September 1, 2018


Reporting to Drew Sloan, Vice President, International Sales, Matthew McCready will lead Semex’s Asian business unit, providing leadership for the ongoing development of our product portfolio, including both Semex’s genetic products and solutions.

“We look forward to Matt contributing to our growth and profitability in these key markets,” says Sloan. “This market, including China, is key to Semex’s future. His passion for connecting with clients and global marketing experience make him a valuable asset to our team.”

Most recently Matt was Director of Business Development, Hybrid Turkeys at Hendrix Genetics, leading their global marketing and working closely with global sales directors and region managers. Previous to that, Matt held several positions at PepsiCo Canada. A graduate of the University of Guelph with a bachelor of commerce, agriculture business, Matt comes from an agricultural background.

Reporting to Paul Krueger, Vice President, Global Key Account & Solutions Strategy, Peter Van Beek will be the lead key account management resource for all of Semex’s European sales teams. Peter will have a hands-on role in our key account strategies and will serve as Semex’s technical expert, working closing with our sales teams to provide our clients with custom solutions.

Peter is excited to return to the AI business after managing a portfolio of calf milk replacers for Nukamel. Previous to that, he was an International ... Read More...

SEMEX'S ELEVATE® PROGRAM DELIVERS FEMALE IMMUNITY+ TEST

Five years after the introduction of Immunity+®, the revolutionary, award-winning genetic technology that was developed by Dr Bonnie Mallard at the University of Guelph, Semex is taking the next step and bringing it to clients worldwide. With the Elevate program, Semex is now offering a genomic test that ranks and selects cows based on their genetic merit along with their Immunity+ genomic test results!   Immunity+ results speak for themselves with results achieved on large commercial herds comprised of 35,000 cows and 75,000 heifers being analysed for disease reduction. It was found that Immunity+ sired animals had anywhere from 2%-20% less disease, depending on which disease was analysed. The most significant reductions in this dataset were found in the traits with the biggest economic impacts, including a 20% reduction in cow mortality among the Immunity+ sired animals. Dairy producers worldwide have seen healthier herds as a result of using Immunity+ sires, resulting in less treatment costs, less drug and antibiotic use and less time spent dealing with sick cows. The introduction of Elevate only speeds up the process.   “With Elevate and its Immunity+ genomic test, producers no longer have to guess which cows are their healthiest,” says Gordon Miller, Semex Sr. Vice President, Sales & Business Development. “Instead, they’re able to tailor their breeding program with both genomic information as well as Immunity+ results categorized as high, average or low health. They’re able to make faster genetic progress towards a stronger, more disease resistant herd, reducing losses and drug use. Immunity+ heritability is 30%, similar to that of milk production. We’re excited for herd health gains that can be made by both identifying female health and utilizing Immunity+ sires!”   Currently available in Canada, the US, Germany and the UK, Elevate and its Immunity+ genomic test supplies Semex clients with the same information as other commercially ... Read More...